787 |
Update on the Core Valve Experience |
Eberhard Grube |
Jul. 21. 09 |
786 |
Why Even Favorable One-Year Data From HORIZONS Shouldn¡¯t Compel DES Usage in AMI |
Renu Virmani |
Jun. 29. 09 |
785 |
New Paradigms of Care for ST-Elevation Myocardial Infarction (STEMI): Focusing on Mortality and Attributable Death Analysis in Cath-Based Care: What Do Device and Drug Trials Teach Us? |
Gregg W. Stone |
Jun. 29. 09 |
784 |
Achieving Optimal Clinical Results After Carotid Stenting: The PROTECT Study and Beyond... |
William A. Gray |
Jun. 23. 09 |
783 |
The Impact of Hemorrhagic Complications on PCI Outcomes: Lessons from ACUITY, HORIZONS and Other Trials |
Roxana Mehran |
Jun. 23. 09 |
782 |
How New Intravascular Imaging Techniques (VH-IVUS, OCT, IR Spectroscopy, and Others) will Change Clinical Practice in the Future |
Gary S. Mintz |
Jun. 23. 09 |
781 |
Is Transcatheter AVR the Standard of Care for High Risk AS Patients? Summary of Worldwide Experiences |
Martin Bert Leon |
Jun. 23. 09 |
780 |
Revived Indications for Thrombus Aspiration During Primary PCI: Unanswered Questions after TAPAS |
Gregg W. Stone |
Jun. 23. 09 |
779 |
TRITON - TIMI 38: The Future Role of Prasugrel (and Other New Anti-Platelet Agents) in PCI |
Roxana Mehran |
Jun. 23. 09 |
778 |
FAME: Physiologic Lesion Assessment is Necessary in Multi-Vessel PCI |
Pim A.L. Tonino |
Jun. 23. 09 |